Zacks Research Has Bullish Estimate for ResMed Q2 Earnings

ResMed Inc. (NYSE:RMD) – Stock analysts at Zacks Research raised their Q2 2025 EPS estimates for ResMed in a research report issued to clients and investors on Tuesday, November 12th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.24 per share for the quarter, up from their prior forecast of $2.19. The consensus estimate for ResMed’s current full-year earnings is $9.22 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.27 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $9.06 EPS, Q2 2026 earnings at $2.32 EPS, Q3 2026 earnings at $2.47 EPS, Q4 2026 earnings at $2.48 EPS, FY2026 earnings at $9.52 EPS and FY2027 earnings at $10.46 EPS.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. The business had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.64 earnings per share.

Several other research analysts have also recently issued reports on the company. Bank of America raised their price objective on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Royal Bank of Canada lifted their price objective on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research note on Friday, October 25th. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Baird R W raised shares of ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Wolfe Research reaffirmed an “underperform” rating and issued a $180.00 price objective on shares of ResMed in a report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $225.70.

ResMed Price Performance

Shares of RMD stock opened at $235.44 on Thursday. The stock’s 50-day simple moving average is $243.48 and its 200-day simple moving average is $223.28. The firm has a market capitalization of $34.56 billion, a price-to-earnings ratio of 31.18, a PEG ratio of 1.81 and a beta of 0.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. ResMed has a fifty-two week low of $144.29 and a fifty-two week high of $260.49.

Hedge Funds Weigh In On ResMed

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of ResMed by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,772,761 shares of the medical equipment provider’s stock worth $1,105,022,000 after purchasing an additional 1,959,642 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of ResMed in the 2nd quarter valued at about $77,285,000. Greenvale Capital LLP increased its position in ResMed by 61.1% during the second quarter. Greenvale Capital LLP now owns 725,000 shares of the medical equipment provider’s stock worth $138,780,000 after buying an additional 275,000 shares during the period. Los Angeles Capital Management LLC raised its position in ResMed by 48.3% in the 2nd quarter. Los Angeles Capital Management LLC now owns 740,226 shares of the medical equipment provider’s stock valued at $141,694,000 after purchasing an additional 241,195 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in ResMed during the 2nd quarter worth $42,036,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total value of $497,480.00. Following the completion of the sale, the director now directly owns 83,204 shares in the company, valued at $20,696,162.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total value of $497,480.00. Following the transaction, the director now owns 83,204 shares of the company’s stock, valued at $20,696,162.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Kaushik Ghoshal sold 5,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total value of $1,262,800.00. Following the transaction, the insider now owns 21,788 shares of the company’s stock, valued at approximately $5,502,777.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,260 shares of company stock worth $14,887,967. 0.71% of the stock is owned by insiders.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.